Peripheral T cell lymphomas (PTCLs) are associated with a poor prognosis due to often advanced disease at the time of diagnosis and due to a lack of efficient therapeutic options. Therefore, appropriate animal models of PTCL are vital to improve clinical management of this disease. Here, we describe a monoclonal CD8 + CD4 2 ab T cell receptor Vb2 + CD28 + T cell lymphoma line, termed T8-28. T8-28 cells were isolated from an un-manipulated adult BALB/c mouse housed under standard pathogen-free conditions. T8-28 cells induced terminal malignancy upon adoptive transfer into syngeneic BALB/c mice. Despite intracellular expression of the cytotoxic T cell differentiation marker granzyme B, T8-28 cells appeared to be defective with respect to cytotoxic activity as read-out in vitro. Among the protocols tested, only addition of interleukin 2 in vitro could partially compensate for the in vivo micro-milieu in promoting growth of the T8-28 lymphoma cells.
Introduction
To develop novel therapeutic strategies for peripheral T cell lymphoma (PTCL) appropriate animal models are crucial [1] . While researchers have been isolating, and also wrongly reisolating [2] , transplantable T cell lymphoma lines since the 1940s from mice after chemical tumor induction/promotion [3] , only recently the ectopic expression of an inducible T cell kinase (ITK)-spleen tyrosine kinase (SYK) fusion gene has allowed to establish the first mouse model of PTCL [1, 4, 5] . To what extent even these genetically induced neoplasias resemble their human pendants is, of course, unclear. Therefore, isolation and characterization of the T8-28 cell line from an un-manipulated BALB/c mouse will be instrumental in furthering our understanding of lymphomagenesis in mice and will help to develop successful therapies for PTCL in humans.
Results and Discussion
T8-28 cells were initially isolated from an un-manipulated adult male BALB/c.OlaHsd mouse kept under standard housing conditions. The animal was found to be paraparetic and, thus, killed for humane reasons. Upon necropsy, spleen and lymph nodes were grossly enlarged containing 1.0610 9 and 1.7610 9 cells, respectively. To determine, whether the secondary lymphoid organ cell suspensions of this animal contained transplantable tumor cells, we injected 1610 7 or 5610 6 splenocytes intravenously into syngeneic BALB/c mice, which induced terminal malignancy in the recipient mice after 12 and 16 days, respectively, ( Figure 1A ) with splenocyte numbers ranging from 4.5610 8 to 1.7610 9 cells in post-mortem analyses. Tumorigenicity of the splenocytes we had isolated was further tested under clinically relevant conditions [6] by injecting 3610 3 cells into lethally irradiated BALB/c.OlaHsd mice followed by re-constitution of hematopoiesis using T celldepletetd bone marrow cells isolated from C57BL/6 mice. In this scenario terminal malignancy developed with a median of 33 days ( Figure 1A ).
The splenocytes we had transplanted consisted by more than 95% of CD8ab + CD4 2 CD3 + TCR + and CD28 + T cells as revealed by fluorescence-activated cell sorting analysis ( Figure 1B , D), indicating that we had isolated a T cell lymphoma which we termed T8-28. Moreover, comparing the lymphoma cells with freshly isolated normal mouse T cells by light microscopy showed that they, indeed, had a lymphoblastic morphology ( Figure 1C ) further corroborating our diagnosis.
The overall expression of lineage and activation markers, including CD25, Ki-67 and granzyme B ( Figure 1D and Table  S1 ), suggested that the T8-28 cells largely resembled fully differentiated cytotoxic T cells with an, at most, oligoclonal TCR repertoire comprising only Vb2 + cells ( Figure 1E ). Polymerase chain reaction DNA sequencing confirmed an in-frame rearrangement of TCR Vb2 and produced a single complementarity-determining region (CDR) 3 sequence revealing that the T8-28 cells actually constitute a monoclonal population. Moreover, knowledge of the CDR3 sequence used by T8-28 cells will allow to track micro-metastases in future experiments in vivo. Therefore, the T8-28 lymphoma is a peripheral T cell lymphoma most likely stemming from a transformed mature CD8 + T cell. Although T8-28 cells expressed markers of cytotoxic T cells they, however, failed to mediate cytotoxicity in re-directed lysis assays against A20J target cells which were readily killed by syngeneic Con A blasts after TCR cross-linking (Figure 2A ). Apart from defective effector functions, de-differentiation of malignant cells, of course, also manifests in uncontrolled growth. Therefore, we analyzed the growth characteristics of T8-28 cells in vitro. Culture of T8-28 cells in medium only led to a rapid decline in cell numbers which was stalled for one day by the addition of recombinant mouse interleukin 15 or 7 and partially reverted by the addition of recombinant human interleukin 2 ( Figure 2B ). So far, long-term in vitro culture of the T8-28 cells beyond day five has, however, not been possible.
Combining recombinant human interleukin 2 with stimulation of CD3 and/or CD28 via bead-coupled monoclonal antibodies led to poorer cell recovery as compared to cultures in the presence of recombinant human interleukin 2 alone ( Figure 2C ). Bypassing The genetic setup and primary structure of the TCR CDR3 region was analyzed by polymerase chain reaction DNA sequencing and the IMGT/V-QUEST program. Please note that TRBV1 in the IMGT nomenclature is identical to designation as Vb2 used throughout this paper and that the *01 allele has originally been found in BALB/c mice which is consistent with the origin of the T8-28 cells. The sequenced Cb part (not shown) could be identified as Cb2 as expected for a TCR-chain using the second DJ cluster. doi:10.1371/journal.pone.0028546.g001 membrane-proximal signaling using PMA and ionomycin also reduced the frequency of viable cells, in this case from 76% to 27% ( Figure 2D ). These data suggest that the downstream signaling machinery of the TCR complex and CD28 is principally intact in T8-28 cells and that the observed induction of cell death upon stimulation of these pathways may be harnessed for therapeutic purposes. Pre-cautions [7, 8] , however, need to be taken when targeting either the TCR complex or CD28 with monoclonal antibodies in humans as a profound activation of normal T cells may induce a toxic 'cytokine storm' [9, 10] . Therapeutically, allogeneic bone marrow transplantations may, of course, also be an option for the T8-28 lymphoma as, indeed, for human PTCL [11] . Most likely, a key component of any graft versus tumor effect in vivo is the recognition and killing of malignant cells by allo-reactive cytotoxic T cells [12] . As shown in Figure 2E , T8-28 cells were susceptible to killing by allogeneic CD8 + T cells in vitro suggesting that a graft versus tumor effect may also be elicited upon allogeneic bone marrow transplantation in vivo.
Taken together, the T8-28 cells constitute a transplantable PTCL line with, at least, partially defective effector functions but maintained susceptibility to killing by allogeneic T cells in vitro. This suggests that this newly established model could provide a basis for the development of novel immunotherapeutic approaches for PTCL in humans.
Materials and Methods

Ethics Statement
All experiments were performed according to the German regulations for animal experimentation and approved by the Regierung von Unterfranken as the responsible authority (Permit Number 55.2-2531.01-82/08 and -28/10).
Mice BALB/c.OlaHsd and C57BL/6.OlaHsd mice were obtained from Harlan-Winkelmann and were used for experiments between six and twelve weeks of age. BALB/c mice were irradiated at the age of nine to ten weeks.
Adoptive transfers of T8-28 cells in vivo
1610 7 , 5610 6 or 3610 3 freshly thawed T8-28 cells were adoptively transplanted intravenously into either un-manipulated or irradiated syngeneic BALB/c.OlaHsd mice as described [13] . After adoptive transfer of T8-28 cells mice were monitored for clinical signs of terminal lymphoma such as severe hunching, poor grooming, lack of spontaneous activity, severe respiratory distress and/or splenomegaly and animals with terminal disease were killed for humane reasons.
Fluorescence-activated cell sorting
The following monoclonal antibodies were used (all Becton Dickinson or Biolegend unless stated otherwise): anti-CD3-FITC (fluorescein isothiocyanate), anti-CD4 Alexa FluorH 647, antiCD8a PE-Cy5 (phycoerythrin-Cy5), anti-CD8b PE, anti-CD25 FITC, anti-T cell receptor (TCR)b PE, anti-TCR Vb 2, 3, 4, 5.1&5.2, 6, 7, 8.1&8.2, 8.3, 9, 10b, 11, 12, 13, 14 and 17a FITC (BD staining panel), anti-Ki-67 PE, anti-Granzyme B PE (eBioscience) and unconjugated anti-CD28 (clone E18) [14, 15] . Gamouse Ig PE (Dianova) was used to detect bound anti-CD28 mAb.
Stainings, including intracellular stainings, were performed with up to 2610 5 T8-28 as described [13] .
Cytospins
Freshly thawed T8-28 cells and purified (99%) lymph node T cells from a C57BL/6 mouse, obtained by negative magnetic selection of cells expressing CD11b, CD11c, CD19, B220, CD49b, CD105, MHC-class II and Ter-119 according to the manufacturer's instructions (Miltenyi), were spun onto slides and stained using the Diff-QuikH staining kit (Medion Diagnostics).
Analysis of the T cell receptor b chain by polymerase chain reaction DNA sequencing RNA of T8-58 cells was extracted by guanidinium thiocyanatephenol-chloroform extraction (TriZol) and transcribed into cDNA using first strand synthesis kit (Fermentas). PCR of cDNA was performed using Vb2-leader (59-GTGGCAGTTTTGCA TTCTGTGCCT-39) and Cbeta specific (59-ACAGTCTGC-TCGGCCCCAGG-39) primers and Phusion polymerase (Finnzymes). The PCR product was separated by agarose gel electrophoresis. The most prominent band of about 800 bp was extracted and sequenced on an ABIMed 3100 machine. The sequence was analyzed by IMGT/V-QUEST programme version: 3.2.20 [16] .
In vitro cultures
All in vitro cultures were carried out using RPMI 1640 medium (PAA) supplemented with 10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, non-essential amino acids, 100 U/ml penicillin and 100 mg/ml streptomycin, 30 mM mercaptoethanol and 2 mM L-glutamine (all Gibco). All cells were incubated at 37uC in the presence of 5% CO 2 .
Cytotoxic activity of T8-28 cells. To assess the cytotoxic potential of T8-28 cells, a fixed number of CFSE-labeled (carboxyfluorescein succinimidyl ester diacetate; 5 mM; invitrogen) A20J cells were co-incubated with freshly thawed T8-28 cells in a 96 well V bottom plate at different effector to target cell ratios for four hours. To trigger re-directed lysis either anti-CD3 mAb 145-2C11 (Biolegend) or anti-b T cell receptor mAb H57-H7 (BD) were added at a final concentration of 10 mg/ml. To assess the susceptibility of A20J cells towards apoptotic stimuli, they were incubated with the anti-CD95 mAb Jo2 (BD) at a final concentration of 0.1 mg/ml. As a positive control for T cellmediated cytolysis we used 'Con A blasts', i.e. lymph node cells (1610 6 /ml) of a BALB/c.OlaHsd mouse which we had preactivated with Concanavalin A (Con A; 5 mg/ml; Sigma) for three days in vitro. After the killing period, viability of the A20J target cells was determined by first counter-staining the cells with prodidium iodide and AnnexinV APC (BD) followed by fluorescence-activated cell sorting analysis. + cells by negative magnetic separation were used. To deplete CD8
+ cells (99%), the spleen/lymph node cell suspension was first stained with an antiCD8a FITC mAb (BD) followed by anti-FITC beads (Miltenyi) and passage over an LD column according to the manufacturer's instructions (Miltenyi) . In further parallel cultures, 2610 6 C57BL/ 6 total spleen/lymph node cells were cultured in the presence of recombinant human interleukin 2 only, i.e. without BALB/c splenocytes. After the pre-incubation period the effector cells were washed and co-incubated with a fixed number of 1610 4 CFSElabeled T8-28 in a 96 well V bottom plate for four hours. Viability of the T8-28 target cells was, again, determined by first counterstaining the cells with propidium iodide and AnnexinV APC (BD) followed by fluorescence-activated cell sorting analysis.
Short term cultures. For short-term activation, freshly thawed T8-28 cells (1610 6 /ml) were re-stimulated in the presence of phorbol myristate acetate (PMA)/ionomycin (5/ 500 ng/ml, Sigma) for four h before fluorescence-activated cell sorting analysis.
Cytokine-and mAb-mediated stimulations. To study the impact of recombinant human IL-2 (ProleukinH, Novartis), recombinant mouse interleukin 7 (R&D) and recombinant mouse interleukin 15 (Biolegend) on the growth and survival of T8-28 cells in vitro, 1610 6 T8-28 cells/ml (48 well plate, Greiner) were cultured in the presence of 10 26 M of exogenously added cytokine. After re-suspension, 200 ml were removed from each well on days one, two and five after initiation of the cultures.
The impact of CD3 and/or CD28 stimulation on T8-28 cell proliferation and survival were studied by incubating freshly thawed T8-28 cells (1610 6 /ml) with 2.5610 6 DynabeadsH Pan Mouse IgG (Dynal) coated with either 10 mg/ml anti-CD3 mAb 145-2C11 (Biolegend), 10 mg/ml anti-CD28 mAb E18 [14, 15] , 10 mg/ml mIgG 1 mAb PPV-06 (Exbio) or 1 mg/ml anti-CD3 plus 0.5 mg/ml anti-CD28 mAb in the presence of 10 26 M recombinant human interleukin 2. In parallel cultures, only recombinant human interleukin 2 was added.
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Table S1 In addition to the data shown in Figure 1B, D 
